Ken Griffin Werewolf Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 700 shares of HOWL stock, worth $1,099. This represents 0.0% of its overall portfolio holdings.
Number of Shares
700
Previous 1,600
56.25%
Holding current value
$1,099
Previous $3,000
66.67%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding HOWL
# of Institutions
69Shares Held
31.8MCall Options Held
700Put Options Held
500-
Ra Capital Management, L.P. Boston, MA6.14MShares$9.65 Million0.18% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.28MShares$6.73 Million6.25% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA3.4MShares$5.34 Million0.42% of portfolio
-
Bio Impact Capital LLC Cambridge, MA2.39MShares$3.75 Million0.79% of portfolio
-
Bank Of America Corp Charlotte, NC2.15MShares$3.38 Million0.0% of portfolio
About Werewolf Therapeutics, Inc.
- Ticker HOWL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,529,400
- Market Cap $46.4M
- Description
- Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...